PMID-37462785 – SS-31 Improves ADP Sensitivity in Aged Mitochondria
Pharaoh G, Kamat V, Kannan S, Stuppard RS, Whitson J, Marinez Guimera A, Rabinovitch PS, Campbell MD, Marcinek DJ. Elamipretide improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT). GeroScience. 2023;45(6):3529-3548.
Quick Reference
| Property | Value |
|---|---|
| PMID | 37462785 |
| DOI | 10.1007/s11357-023-00861-y |
| Year | 2023 |
| Journal | GeroScience |
| Study Type | Animal in vivo |
| Evidence Level | V (Oxford CEBM) |
| Sample | Aged mice (skeletal muscle mitochondria) |
| Peptide(s) Studied | SS-31 |
Key Findings
- SS-31 (elamipretide) restores ADP sensitivity in aged skeletal muscle mitochondria, addressing a fundamental mechanism of age-related bioenergetic decline
- The mechanism involves increased ADP uptake through the adenine nucleotide translocator (ANT), a key inner mitochondrial membrane protein
- Aged mitochondria exhibit reduced ANT-mediated ADP transport, contributing to impaired oxidative phosphorylation; SS-31 reverses this deficit
- The improvement in ADP sensitivity occurred rapidly, suggesting a direct biophysical interaction rather than transcriptional reprogramming
- This finding provides a specific molecular target (ANT) for SS-31's mechanism of action beyond the general cardiolipin-binding model
- Results support SS-31 as an intervention targeting the fundamental bioenergetic deficits of aging rather than downstream consequences
Study Design
Animal in vivo study using aged mice. Skeletal muscle mitochondria were isolated from young and old mice and treated with elamipretide. ADP sensitivity was assessed using high-resolution respirometry. ANT function was evaluated through ADP uptake assays. Cardiolipin content and composition were analyzed. The study combined functional bioenergetics with mechanistic biochemistry to elucidate how SS-31 restores mitochondrial function in aging.
Limitations
- Animal model (mice) — direct translation to human aging mitochondria requires confirmation
- In vivo treatment with ex vivo mitochondrial assessment may not fully recapitulate in situ conditions
- Skeletal muscle focus; effects on other tissues (brain, heart, kidney) may differ
- Acute treatment paradigm does not address whether chronic dosing produces sustained ANT improvements
- Exact binding site and conformational effects of SS-31 on ANT require further structural studies
Clinical Relevance
This study identifies a specific molecular mechanism — ANT-mediated ADP transport restoration — for how SS-31 combats age-related mitochondrial dysfunction. For anti-aging protocols, this provides a clear mechanistic rationale: aging causes reduced ADP sensitivity in mitochondria, leading to impaired ATP production; SS-31 directly restores this. The rapid onset of effect supports the use of SS-31 for acute mitochondrial support, not just chronic supplementation. This research strengthens the scientific foundation for including SS-31 in longevity and anti-aging stacks, directly relevant to Module 10 (Anti-Aging & Longevity).
Related
#research #animal-in-vivo #evidence-level-V #ss-31 #mitochondrial #anti-aging